...
首页> 外文期刊>The journal of sexual medicine >Effectiveness and Safety of Oro-Dispersible Sildenafil in a New Film Formulation for the Treatment of Erectile Dysfunction: Comparison Between Sildenafil 100-mg Film-Coated Tablet and 75-mg Oro-Dispersible Film
【24h】

Effectiveness and Safety of Oro-Dispersible Sildenafil in a New Film Formulation for the Treatment of Erectile Dysfunction: Comparison Between Sildenafil 100-mg Film-Coated Tablet and 75-mg Oro-Dispersible Film

机译:用于治疗勃起功能障碍的新薄膜配方中的锻造型西地那非的有效性和安全性:西地那非100mg薄膜涂层片剂和75mg or-可分散膜的比较

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Background A new oro-dispersible film (ODF) formulation of sildenafil has been developed for the treatment of erectile dysfunction (ED) to overcome the drawbacks that some patients experience when taking the conventional film-coated tablet (FCT). Aim To assess the effectiveness and safety of sildenafil ODF formulation in patients with ED who were using the conventional FCT. Methods From May 2017 through July 2017, 139 patients with ED were enrolled. Data from penile color-duplex ultrasound, medical history, hormonal evaluation, and patient self-administered questionnaires were collected. All patients were administered sildenafil 100-mg FCT for 4 weeks. Thereafter, they underwent a 2-week washout period and subsequently took sildenafil 75-mg ODF for 4 weeks. Outcomes The International Index of Erectile Function (IIEF-15), Hospital Anxiety and Depression Scale (HADS), Patient Global Impressions of Improvement (PGI-I), and Clinician Global Impressions of Improvement (CGI-I) questionnaires were administered and severity of ED was classified as severe (IIEF-15 score ≤ 10), moderate (IIEF-15 score 11–16), or mild (IIEF-15 score?= 17–25). Results All patients completed the final protocol. Differences in mean IIEF scores for erectile function, orgasmic function, sexual desire, and intercourse satisfaction were significantly in favor of sildenafil 100-mg FCT, whereas the mean score for overall satisfaction was in favor of sildenafil 75-mg ODF. A significant difference in changes in HADS score was found from washout to final follow-up (mean difference?=??0.19; P Clinical Implications The ODF formulation of a widely known drug, with the same safety and effectiveness of the FCT, was better appreciated by patients in overall satisfaction. Strengths and Limitations This is the first clinical trial to assess the efficacy of a new formulation of sildenafil in patients with ED. The limitations of the study are related to the methodology used: it was not a case-control study and the patients were not drug-na?ve for ED treatment. Therefore, only the “additional” side effects of the ODF formulation compared with FCT are reported. Conclusion The new ODF formulation is as efficient and safe as the FCT formulation and offers a new choice of treatment to specialists for more precisely tailored therapy. Cocci A, Capece M, Cito G, et?al. Effectiveness and Safety of Oro-Dispersible Sildenafil in a New Film Formulation for the Treatment of Erectile Dysfunction: Comparison Between Sildenafil 100-mg Film-Coated Tablet and 75-mg Oro-Dispersible Film. J Sex Med 2017;14:1606–1611.
机译:摘要背景是开发了西地那非的新oro分散膜(ODF)制剂用于治疗勃起功能障碍(ED),以克服一些患者在服用传统膜涂层片剂(FCT)时的缺点。旨在评估Sildenafil ODF配方在使用常规FCT的患者中的疗效和安全性。方法从2017年5月至2017年7月,注册了139例ED患者。收集来自阴茎色双工超声,病史,荷尔蒙评估和患者自我管理问卷的数据。将所有患者均为Sildenafil 100-Mg FCT施用4周。此后,他们经历了2周的洗涤期,随后服用西地那非75毫克ODF 4周。结果是勃起职能的国际指标(IIEIIE-15),医院焦虑和抑郁症(曾经),患者全球改善印象(PGI-I),以及临床医生的改进全球印象(CGI-I)调查问卷(CGI-I)调查问卷编辑被归类为严重(IIEIIE-15分数≤10),中等(IIEF-15分数11-16)或轻度(IIEF-15分数?= 17-25)。结果所有患者完成最终协议。勃起函数,高潮功能,性欲和性交满足的平均IIET评分的差异显着有利于西地那非100mg FCT,而总体满意度的平均得分有利于西地那非75毫克ODF。从冲洗到最终的随访中发现了患有的变化变化的显着差异(平均差异?= ?? 0.19; P临床意义是一种广泛已知的药物的ODF制剂,具有相同的FCT安全性和有效性,更好患者的整体满意度赞赏。优势和局限性这是第一次评估西地那非在艾德患者中新配方的疗效的临床试验。该研究的局限性与所用方法有关:不是一个案例控制据报道,研究和患者没有药物-NA'VE。因此,报告了与FCT相比的ODF制剂的“额外”副作用。结论新的ODF配方与FCT配方和优惠为高效和安全更精确定制疗法的专家治疗的新选择。Cocci A,Capece M,Cito G,et?Al。Oro-Dispersible Sildenafil在新的电影制剂中治疗时的疗养和安全性CTILE功能障碍:西地那非100mg膜涂层片剂和75mg oro离散膜的比较。 J SEX MED 2017; 14:1606-1611。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号